LESS THAN 5% OF REAL-LIFE PATIENTS WHO SWITCH FROM IV TO SC ABATACEPT IN REAL-WORLD CLINICAL PRACTICE SUBSEQUENTLY SWITCH BACK TO THE IV FORMULATION

Alten, R.Lorenz, H-M.Mariette, X.Nuesslein, H.Galeazzi, M.Navarro, F.Chartier, M.Heitzmann, J.Rauch, C.Le Bars, M.2025-01-072025-01-072017-06-010003-4967https://hdl.handle.net/10668/27639enSubcutaneous formulationLESS THAN 5% OF REAL-LIFE PATIENTS WHO SWITCH FROM IV TO SC ABATACEPT IN REAL-WORLD CLINICAL PRACTICE SUBSEQUENTLY SWITCH BACK TO THE IV FORMULATIONconference outputopen access10.1136/annrheumdis-2017-eular.13791468-2060https://ard.bmj.com/content/annrheumdis/76/Suppl_2/1193.3.full.pdf413181403589